Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAUMADORNASE
2024-512034-14-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Inhaled dornase alfa (Pulmozyme) with Placebo (sodium chloride) (2 arms). Primary endpoint: Incidence of moderate to severe ARDS. Planned start May 2024; status: authorised.
02
Drugs
dornase alfa
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-512034-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512034-14-00.